Ozempic and Wegovy offer more health benefits than just helping you with weight loss. According to a new study, they can help with heart failure symptoms.
Ozempic, Wegovy to Fight Heart Failure
According to a new study, semaglutide, marketed under the brand Ozempic and Wegovy, not only controls diabetes and helps individuals lose weight, but it also has positive effects on the heart. It may improve the quality of life for overweight people with cardiac problems. It is said that lowering body weight will lessen heart failure symptoms, including edema and exhaustion.
A weekly injection of semaglutide over a year improved symptoms like weariness, shortness of breath, and swelling in a trial involving more than 500 patients with obesity and heart failure in 13 countries. They also saw a noticeable gain in their capacity for exercise and physical prowess.
Because it is either overly fragile or not stretchy enough, the heart struggles to pump enough blood to meet the body's needs. The study's participants suffered from a typical kind of heart failure in which the heart pumps correctly but is too stiff to fill fully.
Mikhail Kosiborod, a cardiologist at Saint Luke's Mid-America Heart Institute in Kansas City and the trial's principal investigator, claims that the prevalence of this medical issue has been sharply increasing.
According to Kosiborod, there is mounting proof that obesity in these patients is not merely accidental but may also be the underlying cause of their heart failure. As a result, scientists resorted to semaglutide to determine if the medication may reduce the symptoms by targeting their weight.
Kosiborod said what they observed was "remarkable." Trial participants receiving semaglutide showed a nearly 17-point increase compared to a placebo group, which showed a roughly 9-point improvement on a 100-point scale frequently used to rate symptoms and quality of life in patients with heart failure. Compared to the placebo group, patients on semaglutide lost an average of 13.3 percent of their body weight. Additionally, they performed 20 meters (65 feet) farther in a six-minute endurance test and saw fewer emergency room visits and hospitalizations throughout the year-long trial period.
Experts Warn About Wegovy, Ozempic's Deadly Side Effects
Another study from Chinese researchers warned users about the deadly side effects of Ozempic, Wegovy, and similar fat-loss drugs. According to them, taking those drugs could result in the enlargement of small intestines, putting one at risk of a deadly obstruction of the digestive system.
The medications were tested on mice, and after 20 months of treatment, the researchers saw that the mice's intestines grew larger. The researchers noted that while Wegovy's clinical trials only lasted up to 16 months, they were four weeks too short to detect long-term negative effects.
The researchers cautioned that larger intestines, which are less flexible and thus more prone to obstructions, may develop in persons using GLP-1 medications like Wegovy. They hypothesized that long-term upper intestinal obstruction could result from the small intestine becoming less elastic due to the constant growth in intestinal length and villus height.
A damaged digestive tract, cancer, inflamed or stretched intestines, or blockage that prevents food and liquid from passing through the intestines are all examples of intestinal obstruction. Loss of appetite and constipation are the first symptoms of internal blockage.
RELATED ARTICLE : COVID-19 Booster Shots: Is Your Choice of Vaccine Important? Does It Make a Difference? Experts Explain
Check out more news and information on Medicine & Health in Science Times.
